NWAG
KRYS icon

Net Worth Advisory Group’s Krystal Biotech KRYS Stock Holding History

Net Worth Advisory Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449K Sell
1,207
-100
-8% -$29.9K 0.11% 193
2026
Q1 		$338K Buy
1,307
+384
+42% +$102K 0.07% 272
2025
Q4 		$228K Buy
+923
New +$194K 0.05% 403

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Net Worth Advisory Group's KRYS Position: Q2 2026 in Review

Net Worth Advisory Group reduced its Krystal Biotech (KRYS) stake by 7.7% in Q2 2026, selling an estimated $29.9K and leaving 1,207 shares worth $449K. The position accounts for 0.11% of the portfolio, ranked #193.

Net Worth Advisory Group first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Net Worth Advisory Group held 1,207 shares of Krystal Biotech worth $449K as of Q2 2026.
  • Net Worth Advisory Group sold 100 Krystal Biotech shares in Q2 2026, an estimated $29.9K.
  • Krystal Biotech made up 0.11% of Net Worth Advisory Group's portfolio in Q2 2026, its #193 holding.
  • Net Worth Advisory Group first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.